Summary of findings 2. Cannabinoids compared with other anti‐emetic agent for chemotherapy‐induced nausea and vomiting.
| Cannabinoids compared with other anti‐emetic agent for chemotherapy‐induced nausea and vomiting | |||||||
|
Patient or population: people with chemotherapy‐induced nausea and vomiting Intervention: cannabinoids Comparison: other anti‐emetic agent |
|||||||
| Outcomes | Illustrative comparative risks* (95% CI) | Relative effect (95% CI) | No of participants (studies) | Quality of the evidence (GRADE) | Comments | ||
| Assumed risk | Corresponding risk | ||||||
| Other anti‐emetic agent | Cannabinoids | ||||||
|
Absence of nausea (follow‐up) |
37 per 100 | 56 per 100 (25 to 118) |
RR 1.46 (0.67 to 3.15) | 258 (5) | ⊕⊕⊝⊝ low3,4 | RR > 1 indicates treatment favours cannabinoids | |
|
Absence of vomiting (follow‐up) |
Low‐risk value2 | RR 1.1 (0.86 to 1.4) | 209 (4) | ⊕⊕⊕⊝ moderate3 | RR > 1 indicates treatment favours cannabinoids | ||
| 10 per 1 000 | 11 per 1 000 (9 to 14) |
||||||
| High‐risk value2 | |||||||
| 70 per 100 | 77 per 100 (60 to 98) |
||||||
|
Absence of nausea and vomiting (follow‐up) |
Low‐risk value2 | RR 2.0 (0.74 to 5.4) | 414 (4) | ⊕⊕⊝⊝ low3,4 | RR > 1 indicates treatment favours cannabinoids | ||
| 1 per 100 | 2 per 100 (1 to 5) |
||||||
| High‐risk value2 | |||||||
| 42 per 100 | 84 per 100 (31 to 227) |
||||||
|
Participant preference (follow‐up) |
23 per 100 | 64 per 100 (44 to 92) |
RR 2.8 (1.9 to 4.0) | 799 (9) | ⊕⊕⊝⊝ low3,4 | RR > 1 indicates treatment favours cannabinoids | |
|
Withdrawal any reason (follow‐up) |
19 per 100 | 67 per 100 (27 to 171) |
RR 3.5 (1.4 to 9.0) | 42 (1) | ⊕⊕⊝⊝ low1,3 | RR < 1 indicates treatment favours cannabinoids | |
|
Withdrawal due to lack of efficacy (follow‐up) |
20 per 100 | 19 per 100 (1 to 420) |
RR 0.97 (0.04 to 21) | 118 (2) |
⊕⊝⊝⊝ very low1,3,4 | RR < 1 indicates treatment favours cannabinoids | |
|
Withdrawal due to adverse event (follow‐up) |
3 per 100 | 10 per 100 (4 to 24) |
RR 3.2 (1.3 to 8.0) | 740 (6) | ⊕⊕⊝⊝ low3,5 | RR < 1 indicates treatment favours cannabinoids | |
| *The assumed risk for all outcomes is the median control group risk across studies. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: confidence interval; RR: risk ratio. | |||||||
| GRADE Working Group grades of evidence High quality: Further research is very unlikely to change our confidence in the estimate of effect. Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. Very low quality: We are very uncertain about the estimate. | |||||||
1 Sparse data.
2 The low‐ and high‐risk values are the two extreme proportions of people with a preference for one drug over another.
3 Limitations in the design (cross‐over study) and high attrition.
4 Unexplained heterogeneity.
5 Imprecision.